Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line
- PMID: 2026149
- PMCID: PMC452821
- DOI: 10.1002/j.1460-2075.1991.tb07676.x
Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line
Abstract
We have carried out an analysis of amplified DNA sequences present in a tumorigenic mouse cell line, designated 3T3DM, to determine if the presence of cellular transforming activity is correlated with the elevated expression of any of the amplified genes. These studies utilized a selection protocol that allowed for DNA sequence amplification after the introduction of each gene into non-transformed recipient cells. Cell lines obtained from this selection protocol were assayed for tumorigenicity in nude mice. The results provided evidence that a gene, mdm2, that is amplified more than 50-fold in the 3T3DM cell line, induces tumorigenicity when experimentally overexpressed in NIH3T3 cells and in Rat2 cells. Analysis of the predicted amino acid composition of the mdm2 product(s) revealed features similar to those that have been shown to be functionally significant in certain DNA binding proteins/transcriptional activators. These include two potential metal binding motifs and a negatively charged domain rich in acidic amino acid residues. Overall, the data support the conclusion that mdm2 represents an evolutionarily conserved gene with tumorigenic potential and a predicted role in mechanisms of cellular growth control.
Similar articles
-
Amplification of a gene encoding a p53-associated protein in human sarcomas.Nature. 1992 Jul 2;358(6381):80-3. doi: 10.1038/358080a0. Nature. 1992. PMID: 1614537
-
MDM2 oncogene as a novel target for human cancer therapy.Curr Pharm Des. 2000 Mar;6(4):393-416. doi: 10.2174/1381612003400911. Curr Pharm Des. 2000. PMID: 10788589 Review.
-
Structure and organization of amplified DNA on double minutes containing the mdm2 oncogene.Genomics. 1993 Feb;15(2):283-90. doi: 10.1006/geno.1993.1058. Genomics. 1993. PMID: 8449492
-
The organization and expression of the mdm2 gene.Genomics. 1996 May 1;33(3):352-7. doi: 10.1006/geno.1996.0210. Genomics. 1996. PMID: 8660994
-
The mdm2 proto-oncogene.Leuk Lymphoma. 1997 Jul;26(3-4):227-38. doi: 10.3109/10428199709051772. Leuk Lymphoma. 1997. PMID: 9322885 Review.
Cited by
-
Participation of proteasome-ubiquitin protein degradation in autophagy and the activation of AMP-activated protein kinase.Cell Signal. 2015 Jun;27(6):1186-97. doi: 10.1016/j.cellsig.2015.02.024. Epub 2015 Feb 26. Cell Signal. 2015. PMID: 25728513 Free PMC article.
-
Nerve growth factor receptor negates the tumor suppressor p53 as a feedback regulator.Elife. 2016 Jun 10;5:e15099. doi: 10.7554/eLife.15099. Elife. 2016. PMID: 27282385 Free PMC article.
-
Human Oncoprotein MDM2 Up-regulates Expression of NF-κB2 Precursor p100 Conferring a Survival Advantage to Lung Cells.Genes Cancer. 2011 Oct;2(10):943-55. doi: 10.1177/1947601911436008. Genes Cancer. 2011. PMID: 22701761 Free PMC article.
-
Genome-wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild-type TP53 and receptor tyrosine kinase genes.Clin Transl Med. 2022 Jun;12(6):e882. doi: 10.1002/ctm2.882. Clin Transl Med. 2022. PMID: 35692096 Free PMC article.
-
Adenovirus type 5 early region 1B 55K oncoprotein-dependent degradation of cellular factor Daxx is required for efficient transformation of primary rodent cells.J Virol. 2011 Sep;85(17):8752-65. doi: 10.1128/JVI.00440-11. Epub 2011 Jun 22. J Virol. 2011. PMID: 21697482 Free PMC article.
References
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials